Country of birth | Ukraine | Italy |
Age years | 35 | 65 |
Sex | Female | Male |
Weight kg | 55 | 60 |
Height m | 1.75 | 1.65 |
BMI kg·m−2 | 17.95 | 24.28 |
HIV | Negative | Negative |
Radiology at MDR/XDR-TB diagnosis | Bilateral cavity lesions | Bilateral cavity lesions |
Surgery | No | No |
Previous treatment >30 days n | 2 | 1 |
Drugs received during previous treatments | Am, Clr, Cs, E, Eto, H, Ipm, Lzd, Mfx, PAS, R, S, Z | E, H, Lfx, R, S, Z |
Drug-resistance at MDR/XDR diagnosis | Am, Cm, E, Eto, FQ, H, Km, R, S, Z | E, Eto, FQ, H, R, S, Z |
Drugs used in treatment | Amx/Clv, Bd, Cfz, Lzd, Mp, Trd | Amx/Clv, Bd, Cfz, Lzd, Mp, Trd |
Hospital admission days | 91 | 101 |
Smear conversion days | 63 | 58 |
Culture conversion days | 75 | 58 |
Bedaquiline exposure days | 180 (September 10, 2012 to March 8, 2013) | 180 (November 23, 2012 to May 21, 2013) |
Adverse events | Anorexia, depression | Generalised anxiety, deafness, diarrhoea |
Ad interim outcome | Clinically and radiologically improved, consistently bacteriologically negative, at the last clinical examination at 15 months (July 3, 2013) | Clinically and radiologically improved, consistently bacteriologically negative, at the last clinical examination at 13 months (July 12, 2013) |
Treatment duration | On 15th month of treatment with Amx/Clv, Cfz, Lzd, Trd (439 days) | On 13th month of treatment with Amx/Clv, Lzd, Trd (387 days) |
Directly observed treatment performed | Yes | Yes |
BMI: body mass index; Am: amikacin; Clr: clarithromycin; Cs: cycloserine; E: ethambutol; Eto: ethionamide; H: isoniazid; Ipm: imipenem; Lzd: linezolid; Mfx: moxifloxacin; PAS: para-aminosalycilic acid; R: rifampicin; S: streptomycin; Z: pyrazinamide; Lfx: levofloxacin; Cm: capreomycin; FQ: fluoroquinolone; Km: kanamycin; Amx: amoxicillin; Clv: clavulanate; Bd: bedaquiline; Cfz: clofazimine; Mp: meropenem; Trd: terizidone.